anselamimab + cyclophosphamide + bortezomib + dexamethasone

A quadruplet **combination cancer therapy** comprised of anselamimab (a monoclonal antibody targeting CD38), cyclophosphamide (an alkylating agent), bortezomib (a proteasome inhibitor), and dexamethasone (a synthetic glucocorticoid corticosteroid). This regimen is designed for the treatment of multiple myeloma or related plasma cell disorders. Mechanistically, **anselamimab** induces antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity against CD38-expressing malignant plasma cells. **Cyclophosphamide** alkylates DNA, leading to cytotoxicity mainly in rapidly dividing cells. **Bortezomib** inhibits the 26S proteasome, disrupting protein homeostasis and triggering apoptosis in myeloma cells. **Dexamethasone** modulates immune and inflammatory signaling through the glucocorticoid receptor, reducing cytokine production and lymphocyte function, with direct cytotoxic activity against plasma cells. The combination is intended to maximize antitumor efficacy by targeting malignancy through immunologic, cytotoxic, and apoptosis-promoting mechanisms. It is primarily used in multiple myeloma, potentially both newly diagnosed and relapsed/refractory settings.

Other names

VCAD